Thus, we aimed to explore the differences in mtDNA extracted from CD4+ T cells between patients with a recent diagnosis of either Clinically Isolated Syndrome (CIS) or Relapsing–Remitting MS (RRMS) and healthy controls (HC). This evidence concerns the gene CD4 and in situ carcinoma.